|
|
| |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Medicinal Chemistry Group |
|
Interests |
| |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
The NESACS Medicinal Chemistry Group
|
- by Mindy Levine |
| |
|
|
When Dr. Raj Rajur left ArQule
Corporation in 2001 to start his own company, very
few of his colleagues were interested in joining him. “When
you have very preliminary ideas, it is hard to convince
people to support you,” said Dr. Rajur.
His company, Creagen Biosciences, now employs 24
chemists, who are divided between sites in Woburn,
MA, and India.
The goal of Creagen Biosciences is to provide medicinal
chemistry knowledge and expertise to biotechnology
companies. “We specialize in creating intellectual
property for biotechs,” said Dr. Rajur. For example,
Creagen Biosciences developed a compound for Mercury
Therapeutics, Inc., that had nanomolar potency against
the biological target. |
| MedChem symposia |
Dr. Rajur heads the
Medicinal Chemistry (MedChem) group of the Northeastern
Section of the American Chemical Society (NESACS),
which is a position that he has held since 2004.
The MedChem group, one of the largest and most
active subgroups in NESACS, organizes three annual
symposia. The goal of the symposia is to “cover cutting-edge
topics in the pharmaceutical and biotech industries,” according
to Dr. Rajur. Each symposium focuses on a particular
therapeutic field. For example, past symposia have
focused on advances in the treatment of Alzheimer’s
Disease, which affects more than 35 million people
worldwide, and on the treatment of Type II Diabetes,
also an extremely common affliction.
The most recent symposium
took place in May, 2010, in conjunction with
Sino-American Pharmaceutical Professionals Association
(SAPA-NE). The topic of this symposium was “Discovery in China:
Status Opportunity, International Collaboration,
and Challenges.” The choice of this topic
recognizes the increasing role that China and other
Asian countries play in the pharmaceutical industry,
as many companies find it more cost-effective to
conduct some chemistry research in these countries.
Additionally, the symposia provide a networking
opportunity for chemists from industry and academia
to interact. Students who may be interested in
a career in the pharmaceutical industry are highly
encouraged to attend and network with representatives
of local pharmaceutical companies. In addition
to the scientific talks, Dr. Mukund Chorghade,
past NESACS chair and CSO at THINQ Pharma, often
provides a one-hour career guidance and consulting
session during the symposia, which assists students,
as well as other chemists who are seeking employment
in the pharmaceutical industry.
The MedChem group is “doing very new things
that we haven’t been doing before,” said
Dr. Chorghade. “I am just delighted.” |
| Relationship with NESACS |
| The MedChem group plays an
important role in the larger NESACS organization.
Two of the three annual symposia are hosted in conjunction with the monthly
NESACS meeting, and one symposium is held independently. Additionally, the
NESACS website (www.nesacs.org) has a section devoted to the MedChem group. |
| History of MedChem |
The MedChem group used
to meet monthly at a restaurant in Sturbridge,
said Dr. Patrick Gordon, chemistry lecturer at
Emmanuel College and past chair of the MedChem
group. However, very few chemists attended the
monthly meetings, which included a chemistry
seminar given by an external speaker. “Clearly
we weren’t meeting the needs of our clientele,” Dr.
Gordon said, as sometimes the only people who
attended the meetings were the members of the
MedChem board.
When Dr. Rajur assumed the
position as chair of the MedChem group in 2004,
he significantly modified the structure of the
group and its programming, moving to the current
format of three annual symposia. The group’s
popularity has increased dramatically as a result.
For example, approximately 70 chemists attended
the December, 2009 symposium on “Recent
Developments in RNAi Therapeutics,” which
was held in Burlington, MA.
Another relatively recent
change in the MedChem group’s organization
is the source of funding for events. The chair-elect
used to be responsible for procuring funds from
various pharmaceutical companies, which would
be used to invite speakers to the monthly meetings.
Funding for the symposia now comes partly from
NESACS and partly from local pharmaceutical sponsorships,
Dr. Gordon said. |
| Future Directions |
Dr. Rajur would love to
see more people involved in the MedChem group.
In particular, chemists are encouraged to get
involved in planning the symposia and choosing
relevant therapeutic topics for the events. The
MedChem group conducts a long-range planning
meeting once a year, at which time the topics
of the symposia (and potential speakers) are
chosen. Another future direction that Dr. Gordon
suggested would be the establishment of a MedChem
prize to recognize an important local medicinal
chemist. This prize could be presented annually
at the December MedChem symposium.
Yet another area for future
development would be the elaboration of the NESACS
website to include more medicinal chemistry-specific
content. Dr. Rajur would like to add “fun
and interactive chemistry links” to the
MedChem section of the NESACS website. Dr. Rajur
would also like to add links and advice to help
students successfully transition from the academic
world to a pharmaceutical position, which is
often a challenging career move. Links that help
visitors volunteer for and contribute to the
MedChem group would also be desirable. |
| Conclusions |
“What I am particularly
proud of is that we represent chemists from industry,
academia, and government,” said Dr. Chorgade. “This
diverse group brings a fresh perspective to the
table.”
“The people who established
this group were the real pioneers,” concluded
Dr. Gordon. “They saw the vision and necessity
of having a MedChem group. We continue to benefit
from that vision today.” |
|
|
| |
|
2010
Annual Report Medicinal Chemistry Group |
Dr. Raj (SB) Rajur, Program Chair for Medicinal
Chemistry Division, NESACS
|
| The Medicinal
chemistry division is one of the active groups of
NESACS that conducted two excellent symposia during
the year 2010. The first symposium was held on May
22, 2010, and the topic was DRUG R&D
IN CHINA-Status, Opportunity, International Collaboration
and Challenge. It was a day-long symposium
held at the Holiday Inn, Woburn, MA. There were ten
speakers and the program was attended by more than
120 people. |
| The second symposium, EMERGING
TREATMENTS FOR CNS DISORDERS, was held
on December 9, 2010 at Hilton Hotel in Woburn,
MA. There were 100 participants who enjoyed cutting
edge research results that were presented by four
well-known speakers from academia and the pharmaceutical
industry: |
Dr.
Ian Bell, Merck, West Point, PA, spoke
on “The Discovery of Orally Bioavailable
CGRP Receptor Antagonists: From Concept to Clinical
Efficacy.” |
| Dr. Larry
Hardy, Director of Pharmacology, Sepracor
Corporation, Marlborough, MA, spoke on the topic “Why
all the excitement about glutamate?” |
| Dr. Edward
Holson, Director of Medicinal Chemistry,
Stanley Center for Psychiatric Research, The Broad
Institute of MIT and Harvard, Cambridge, MA, spoke
on the topic, “HDACs in memory and cognition:
Development of isoform selective inhibitors with
improved CNS drug properties.” |
| The keynote presentation
for the evening was presented by speakers from RepliGen
Corporation, Waltham, MA. Dr. James Rusche,
Senior Vice-President of Research and Development,
and Vincent Jacques, Senior Director
of Preclinical Development, were the lead speakers.
The topic was “HDAC Inhibitors for CNS
Diseases: Challenges in Selectivity and Pharmacology.” |
| A social hour,
networking, and dinner were parts of the program.
The program chair, Dr. Raj (SB) Rajur,
CreaGen Biosciences welcomed the guests and participants. Dr.
Norton Peet, Director of Chemistry, Micro-biotix,
moderated the symposium. The symposium was concluded
with a token of respect to the speakers by Dr. Rajur. |
|
|
|
| |
| |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|